Wedbush Starts Immunome With Outperform Rating, $12 Price Target; Has Positive View for Early-Stage Pipeline of Targeted Cancer Therapies
Wedbush Starts Immunome With Outperform Rating, $12 Price Target; Has Positive View for Early-Stage Pipeline of Targeted Cancer Therapies
Wedbush 以跑赢大盘的评级创业 Immunome,目标股价为12美元;对早期靶向癌症疗法的研发持乐观态度
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册